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Abstract
Aim: To analyze alcohol use, clinical data and laboratory parameters that may affect FIB-4, an index for measuring liver
fibrosis, in HCV-monoinfected and HCV/HIV-coinfected drug users.
Patients and Methods: Patients admitted for substance abuse treatment between 1994 and 2006 were studied. Socio-
demographic data, alcohol and drug use characteristics and clinical variables were obtained through hospital records. Blood
samples for biochemistry, liver function tests, CD4 cell count, and serology of HIV and HCV infection were collected at
admission. Multivariate linear regression was used to analyze the predictors of FIB-4 increase.
Results: A total of 472 (83% M, 17% F) patients were eligible. The median age at admission was 31 years (Interquartile range
(IQR) 27–35 years), and the median duration of drug use was 10 years (IQR 5.5–15 years). Unhealthy drinking (.50 grams/
day) was reported in 32% of the patients. The FIB-4 scores were significantly greater in the HCV/HIV-coinfected patients
(1.14, IQR 0.76–1.87) than in the HCV-monoinfected patients (0.75, IQR 0.56–1.11) (p,0.001). In the multivariate analysis,
unhealthy drinking (p = 0.034), lower total cholesterol (p = 0.042), serum albumin (p,0.001), higher GGT (p,0.001) and
a longer duration of addiction (p = 0.005) were independently associated with higher FIB-4 scores in the HCV-monoinfected
drug users. The effect of unhealthy drinking on FIB-4 scores disappeared in the HCV/HIV-coinfected patients, whereas lower
serum albumin (p,0.001), a lower CD4 cell count (p = 0.006), higher total bilirubin (p,0.001) and a longer drug addiction
duration (p,0.001) were significantly associated with higher FIB-4 values.
Conclusions: Unhealthy alcohol use in the HCV-monoinfected patients and HIV-related immunodeficiency in the HCV/HIV-
coinfected patients are important risk factors associated with liver fibrosis in the respective populations
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Introduction
Liver fibrosis is the main predictor of whether chronic hepatitis
C will progress to cirrhosis and end-stage liver disease [1]. Because
the complications of liver disease mainly occur in patients with
advanced-stage fibrosis, assessing chronic hepatitis C early is
essential when evaluating at-risk patients [2]. In Western
countries, more than 50% of new HCV infections are associated
with drug abuse. However, this particular population also has
lower rates of clinical assessment and chronic hepatitis C
treatment. Given the likelihood of new and more effective
treatments, drug abusers with chronic hepatitis C would benefit
from simple, non-invasive measurements of liver fibrosis.
The cofactors associated with chronic hepatitis C progression
differ among studies; alcohol abuse, male gender, age at infection,
body mass index, and coinfection with human immunodeficiency
virus infection (HIV) and Hepatitis B virus infection (HBV) have
been related to more rapid disease progression [1–5]. In HCV/
HIV-coinfected individuals, CD4 cell counts below 200 cells/mL
have been associated with liver fibrosis progression [6]. In parallel,
highly active antiretroviral therapy (HAART) has been shown to
reduce liver-related deaths [7,8].
In HIV-negative patients, it is well established that alcohol
abuse and HCV infection have a synergistic effect on liver fibrosis.
However, there are conflicting results regarding the independent
effect of alcohol on liver damage in HCV/HIV-coinfected patients
[6,9,10].
Liver biopsy is the gold standard for assessing fibrosis [11].
However, assessing liver disease through an invasive procedure is
unlikely in patients with substance abuse [12]. Furthermore,
eligibility for chronic hepatitis C treatment in this population is
low compared with eligibility in other populations [13,14]. To
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a certain extent, the evolution of liver disease in drug abusers
parallels the natural history of chronic hepatitis C.
Several non-invasive markers of liver fibrosis have been
proposed as alternatives to liver biopsy. Some of these markers
reflect the modified extracellular matrix turnover that occurs
during fibrogenesis [15,16], whereas others reflect alterations in
hepatic function [17,18]. FIB-4 was initially described in 2006
[18], and since then, it has been proposed as reliable marker of
fibrosis in both HCV-monoinfected and HCV/HIV-coinfected
individuals [18,19]. FIB-4 correlates well with liver biopsy in
patients with and without advanced fibrosis [20,21]. Moreover,
non-invasive markers of liver fibrosis have been proposed as
predictors of all-cause and liver-related mortality [22,23].
Although abuse of alcohol and illegal drugs is frequent in
patients with HIV infection and HCV infection, it is unclear how
non-invasive liver fibrosis tests may reflect disease progression. In
this study, we hypothesize that certain clinical and laboratory
characteristics may influence a simple index of fibrosis and that the
cofactors associated with elevated FIB-4 scores may differ between
HCV-monoinfected patients and HCV/HIV-coinfected patients.
Hence, the primary objective of the study was to characterize the
putative differences in risk factors for elevated liver function
biomarkers between HCV-monoinfected and HCV/HIV-coin-
fected patients.
Patients and Methods
Study Population
This was a cross-sectional study of patients admitted for
substance abuse treatment between 1994 and 2006. The de-
mographic and drug use characteristics were recorded through
a structured questionnaire administered by a physician the day of
admission. Questions related to drug and alcohol abuse included:
(i) the main drug of abuse (type of drug, age at first use, duration of
drug use and route of administration), (ii) poly-drug use (yes/no)
(iii) alcohol consumption: do you regularly drink alcohol? (yes/no);
if yes, do you drink 5 or more standard drinks per day?. A
standard drink unit contains 12–14 grams of alcohol and
unhealthy alcohol consumption was defined as a daily alcohol
intake $50 grams (g) [24,25] in the 6-month period prior to
admission. All participants gave written informed consent. The
methods used in this study complied with the ethical standards for
medical research and principles of good clinical practice defined
by the World Medical Association’s Declaration of Helsinki. The
study was approved by the Ethics Committee of the Hospital
Universitari Germans Trias i Pujol.
Routine laboratory parameters, including liver function tests
and serology for HIV infection and HCV infection, were analyzed
at admission. Other characteristics of admission for substance
abuse treatment have been described elsewhere [26].
The liver function tests and biochemical parameters were
assessed using an Olympus 5200 Multichannel chemistry analyzer.
The procedure, which remained the same throughout the study,
was based on the reference method recommended by the
International Federation of Clinical Chemistry.
HIV infection was identified by an enzyme-linked immunosor-
bent assay. Repeatedly reactive samples were confirmed by the
Western immunoblot technique.
HCV infection was assessed prior to or during admission by
a second- or later-generation enzyme immunoassay (Ortho
Diagnostics, Raritan, NJ). The positive samples were confirmed
by either a recombinant immunoblot assay (RIBA HCV 2 SIA,
Chiron Corporation, Emeryville, CA) or a qualitative/quantitative
assay (COBAS AMPLICOR, Roche Diagnostic Systems, Branch-
burg, NJ).
Outcome
The primary outcome was the FIB-4 score, which was
calculated as
FIB4~
Age½years|AST ½U=L
Platelet½109L| ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiALT ½U=Lp
FIB-4 scores lower than 1.45 indicate lack of liver fibrosis with
a negative predictive value of 90% and a sensitivity of 70% [18].
FIB-4 scores greater than 3.25 indicate significant liver fibrosis
with a positive predictive value of 65% and a specificity of 97%
[18].
Statistical Analysis
All of the analyses were conducted separately for the HCV-
monoinfected (N= 228) and the HCV/HIV-coinfected (N= 244)
individuals. We used medians and interquartile ranges (IQRs) to
describe the quantitative variables and absolute frequencies and
percentages to describe the qualitative variables.
The distribution of FIB-4 score was strongly skewed to the right
(i.e., there were several very high values); we therefore normalized
it for analysis purposes using a logarithmic transformation.
We used multiple linear regression models to determine the
FIB-4 predictive values of the variables. There were three types of
predictors: (1) binary, which included sex, alcohol use, and HBsAg;
(2) continuous on a natural (additive) scale, which included body
mass index (BMI), CD4 cell count, total cholesterol, alkaline
phosphatase, and duration of drug use; and (3) continuous on
a logarithmic (multiplicative) scale, which included total bilirubin,
serum albumin, and GGT. The decision to analyze a variable
using a logarithmic scale was based on the need to reduce the
undue influence of high values in predictors with strong right
skewness.
The interpretation of the regression coefficients differed among
the three types of predictors. Specifically, the regression coeffi-
cients of the binary variables represented the percentage FIB-4
difference between those with and without the condition; the
regression coefficients of the additive continuous variables
represented the percentage FIB-4 difference associated with an
unitary increase or decrease in the variables, and the regression
coefficients of the multiplicative continuous variables represented
the percentage FIB-4 difference associated with an increment or
decrement in the variables.
The intercept represented the expected FIB-4 score in an
individual with zero values for all of the predictors.
The test results were considered to be statistically significant if
the resulting P-value was ,.05. The statistical analysis was
performed using the SPSS software, version 15.0.1 (SPSS,
Chicago, IL, USA).
Results
Patients were eligible for this study if they had chronic HCV
infection (N= 544). Patients with aminotransferase levels 10 times
greater than the upper limit of the normal range (N= 5,1.0%),
patients who had received HCV antiviral therapy (N= 6,1.1%)
and patients with antecedent of decompensated liver cirrhosis
(N= 10,1.8%) were excluded. In addition, patients with an HCV-
RNA level below the limit of detection (,50 IU/mL) were
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excluded (N=9, 1.7%). Finally, patients with outlier laboratory
values and those with incomplete data for calculating FIB-4 score
were also excluded (N= 42, 7.7%). After these exclusions, the
study population consisted of 472 patients and 244 patients (52%)
were coinfected with HIV. Table 1 shows the descriptive statistics
at admission for the entire group and for the HCV-monoinfected
(N= 228) and HCV/HIV-coinfected (N=244) subgroups. Over-
all, 17% of the patients were women, the median age at admission
was 31 years (IQR 27–35 years), the median BMI was 22 kg/m2,
the median duration of drug use was 10 years, and unhealthy
drinking was reported in 32% of the patients. In addition to
decreased CD4 cell counts, the HCV/HIV-coinfected patients
had a longer median drug use duration, an increased frequency of
unhealthy alcohol intake, lower levels of total cholesterol, higher
levels of GGT and a higher prevalence of HBsAg than those
infected with HCV only. The median AST and ALT levels and
platelet counts were 35 U/L, 47 U/L, and 180 6 109/L,
respectively.
Thirty-one percent of the HIV-positive patients were receiving
antiretroviral therapy at admission, and 48% had never received
antiretroviral therapy.
The median FIB-4 score at admission was 0.93 (IQR 0.65–
1.46); it was significantly higher in the HCV/HIV-coinfected
patients (1.14, IQR 0.76–1.87) than in the HCV-monoinfected
patients (0.75, IQR 0.56–1.11). Figure 1 shows the distribution of
the FIB-4 scores in the two groups on both natural and logarithmic
scales. As can be seen in the bottom panels of Figure 1, the log-
transformed FIB-4 scores approximately followed a normal
distribution, rendering normally based methods appropriate for
the analysis.
Regression Analysis of FIB-4 (Log Scale)
We conducted univariate regressions of the variables shown in
Table 1 against the log-transformed FIB-4 scores; only the
variables that define FIB-4 were not used in the univariate
regressions. The two columns with univariate headings in Table 2
show the results of the univariate analyses separately for the
monoinfected and coinfected patients.
In the univariate models for the HCV-monoinfected patients,
unhealthy alcohol use, higher BMI, longer duration of drug use,
lower cholesterol, higher bilirubin, lower albumin, and higher
GGT were significantly associated (p,0.05) with higher FIB-4
scores. In the coinfected patients, higher FIB-4 scores were found
to be significantly associated (p,0.05) with a longer drug use
duration, lower cholesterol, higher alkaline phosphatase, lower
CD4 cell count, higher bilirubin, lower albumin, and higher GGT.
For each group, the variables that showed significant relation-
ships in the univariate analyses were used in a multivariate model.
In the multivariate model for the HCV-monoinfected patients,
unhealthy alcohol use (p = 0.034), longer drug use duration
(p = 0.005), lower cholesterol (p = 0.042), lower albumin
(p,0.001), and higher GGT (p= 0.001) continued to be signifi-
cantly associated with higher FIB-4 scores.
In the coinfected patients, longer drug use duration (p,0.001),
lower CD4 cell count (p = 0.007), higher bilirubin (p,0.001), and
lower albumin (p,0.001) were significantly associated with higher
FIB-4 scores.
Longer drug use duration and lower albumin levels were
significantly associated with increased FIB-4 scores in both groups.
By contrast, unhealthy alcohol use was strongly predictive of high
FIB-4 scores only in the HCV-monoinfected group; similarly, high
Table 1. Descriptive statistics (median [IQR] or n (%)) of HCV-monoinfected and HCV/HIV-coinfected patients at admission to
substance abuse treatment.
HCV HCV/HIV Total
N=228 N=244 p_value* N=472
Socio-demographic and anthropometric
Females 35 (15.4%) 45 (18.4%) 0.371 80 (16.9%)
Age, years 30 [26,34] 31.5 [28, 35] 0.008 31 [27, 35]
Body mass index, kg/m2 (N=421) 22.3 [20.7, 24.6] 21.6 [19.6, 23.6] 0.000 21.9 [20.2, 23.9]
Drug use
Unhealthy alcohol use (N=440 ) 62 (28.2%) 79 (35.9%) 0.082 141 (32.0%)
Duration of drug use, years (N=463) 7.6 [3.5, 12.0] 12.0 [7.6, 16.0] 0.000 10.0 [5.5, 15.0]
Laboratory parameters
Hepatitis B surface Antigen (N=440 ) 9 (4.2%) 15 (6.7%) 0.243 24 (5.5%)
Total cholesterol, mg/dL 162 [143, 178] 149 [128, 170] 0.001 155 [135, 174]
Alkaline Phosphatase, U/L 70 [55, 82] 70 [59, 86] 2.664 70 [56, 84]
Total bilirubin, mg/dL 0.4 [0.3, 0.6] 0.4 [0.3, 0.6] 0.297 0.4 [0.3, 0.6]
Albumin, g/L (N=438) 39 [36, 42] 38 [35, 41] 0.013 39 [36, 41]
GGT, U/L 33 [19, 62] 44.5 [24, 93] 0.052 38 [22, 76]
CD4 lymphocytes, cells/mL (N=456) 1225 [933, 1428] 383 [204, 661] 0.000 742 [350, 1225]
Laboratory components of FIB-4
Platelets, 109/L 197 [166, 243] 163 [127, 196] 0.000 180 [146, 224]
AST, U/L 33.5 [21.0, 61.0] 37.5 [24.2, 61.0] 0.907 35.0 [23.0, 61.0]
ALT, U/L 54.0 [23.0, 98.0] 43.0 [25.0, 71.0] 0.001 47.0 [24.0, 84.0]
*p value for the comparison between HCV-monoinfected and HCV/HIV-coinfected patients; p values correspond to x square test in categorical variables and t test for
differences of mean values in continuous variables.
doi:10.1371/journal.pone.0046810.t001
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total bilirubin levels were associated with higher FIB-4 scores only
in the coinfected patients.
Although the primary aim of the study was the characterization
of the variables that were associated with FIB-4 increase in HCV-
monoinfected and HCV/HIV-coinfected, the intercepts of the
multivariate models provide a means of comparing a hypothetical
HCV-monoinfected individual with a hypothetical HCV/HIV-
coinfected individual, assuming that both have 900 CD4 cells/mL
and that all of the other variables are equal. The slightly increased
FIB-4 intercept value (0.778 in the monoinfected and 0.875 in the
coinfected patients) was not statistically significant (p = 0.218).
However, for each decline of 100 CD4 cells/mL among the
coinfected patients, there was a significant FIB-4 increase of 3.6%
(p= 0.007) (Table 2).
To further characterize the differential effect of unhealthy
alcohol use on FIB-4 scores, Figure 2 shows the distributions of the
FIB-4 scores in the four groups by alcohol consumption and HIV
coinfection. Figure 2 shows box plots that are graphically
enhanced to show the 2.5th, 5th, 10th, 25th, 50th, 75th, 90th, 95th
and 97.5th percentiles of the FIB-4 distribution. It is clear from
Figure 2 that the primary difference was between the non-drinking
HCV-monoinfected patients and the other three groups. In
particular, the increased FIB-4 score due to unhealthy alcohol
use among the HCV-monoinfected patients was similar to the
effect of HIV-related immunodeficiency among the non-drinkers.
The additional increase in FIB-4 among the coinfected individuals
with unhealthy alcohol use was small and not significant
(p = 0.695).
Discussion
Individuals with histories of drug use account for the majority of
new hepatitis C infections in Western countries. This population is
at risk for liver fibrosis, and a number of disease progression
cofactors highlight the relevance of medical assessment. Evaluating
liver fibrosis via non-invasive tests early in the course of drug
addiction may increase the proportion of patients who are eligible
for treatment. This study of young adults with chronic hepatitis C
shows that the factors associated with higher FIB-4 scores clearly
differed between the HCV-monoinfected and HCV/HIV-coin-
fected individuals.
The main contribution of the study is related to the fact that
unhealthy alcohol use had a differential effect on FIB-4 values if
patients have hepatitis C alone or HCV/HIV coinfection.
Unhealthy alcohol drinking has been regarded as a major
contributor to the progression of liver disease in the setting of
chronic hepatitis C [27] and, a synergistic effect between HCV
and alcohol has been proposed [28]. However, even though
Figure 1. Distribution of FIB-4 score and log FIB-4 score according to HCV-monoinfection and HCV/HIV-coinfection.
doi:10.1371/journal.pone.0046810.g001
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alcohol use is among the cofactors related with liver fibrosis in
coinfection in studies with liver biopsy [6,29], the present and
other studies that have used non- invasive methods to estimate
fibrosis [9,10], does not detect an additional effect of alcohol
drinking on the FIB-4 of HCV/HIV-coinfected patients.
In coinfected patients with unhealthy alcohol consumption, the
FIB-4 does not reflect the negative impact of alcohol intake on
liver fibrosis. Therefore, clinicians may not be able to assess the
impact of ethanol nor can advise the patient on the risk of disease
progression. On the contrary, unhealthy alcohol use is reflected in
Table 2. Percentage change in FIB-4 score associated with differences in predictors of higher FIB-4 scores.
HCV-monoinfected HCV/HIV-coinfected
N=228 N=244
Univariate Multivariate Univariate Multivariate
Variable % (p_value) % (p_value) % (p_value) % (p_value)
Intercept NA 0.778* NA 0.875**
(95% CI : 0.705, 0.861) (95% CI: 0.762, 1.005)
Female to Male 211.6% (0.266) +11.5% (0.343)
Unhealthy alcohol use +46.7% (,.001) +20.6% (0.034) +3.9% (0.695)
HBsAg positive +25.1% (0.268) +31.3% (0.155)
BMI: increase of 1 kg/m2 +4.3% (0.001) +2.2% (0.069) +0.8% (0.609)
Duration of drug use: increase of 5 years +9.4% (0.007) +10.0% (0.005) +21.5% (,.001) +13.9% (,.001)
Cholesterol: decrease of 20 mg/100 mL +5.4% (0.018) +4.5% (0.042) +6.6% (0.006) +2.4% (0.318)
Alkaline Phosphatase: increase of 10 U/L +2.7% (0.108) +4.9% (0.001) +0.9% (0.618)
CD4: decrease of 100 cells/mL NA NA +5.2% (,.001) +3.6% (0.007)
Bilirubin: 1.5-fold increment +12.7% (,.001) +5.7% (0.097) +22.8% (,.001) +22.2% (,.001)
Albumin: 1.1-fold decrement +19.8% (,.001) +19.1% (,.001) +15.4% (,.001) +12.9% (,.001)
GGT: 2-fold increment +20.3% (,.001) +12.3% (0.001) +16.4% (,.001) +7.3% (0.061)
*Expected value of FIB-4 for individuals with predictors at BMI = 22 kg/m2, no alcohol consumption, total cholesterol = 155 mg/100 mL, Total bilirubin = 0.4 mg/dL,
albumin = 39 g/L, GGT = 38 U/L, and duration of IDU = 10 years.
**Expected value of FIB-4 for individuals with predictors at CD4 = 900 cells/mL, total cholesterol = 155 mg/100 mL, total bilirubin = 0.4 mg/dL, albumin = 39 g/L, Alkaline
Phosphatase = 70 U/L, GGT = 38 U/L, and duration of IDU = 10 years.
doi:10.1371/journal.pone.0046810.t002
Figure 2. Distribution of FIB-4 scores according to unhealthy alcohol use in HCV-monoinfected and HCV/HIV-coinfected patients.
doi:10.1371/journal.pone.0046810.g002
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the FIB-4 of the monoinfected patients thus making possible
preventive interventions to reduce harm.
Unhealthy alcohol use in the HCV-monoinfected patients and
HIV-related immunodeficiency in the HCV/HIV-coinfected
patients are the most important cofactors associated with fibrosis
progression in the respective populations. In addition, we found
that drug use duration and serum albumin were correlated with
the FIB-4 scores of both the monoinfected and coinfected patients,
whereas unhealthy alcohol use, GGT and total cholesterol were
associated with higher FIB-4 scores only in the monoinfected
patients. The effect of HIV-related immunodeficiency in the
coinfected patients was strong (an increase of 3.5% in the FIB-4
score for every 100 CD4 cells/mL decrease). Furthermore, we did
not observe differing FIB-4 values between the HCV-mono-
infected and coinfected individuals with CD4 cell counts above
900 cells/mL. This observation suggests that FIB-4 elevation is
associated with immunoactivation and the resulting decrease of
CD4 cell counts in HCV/HIV-coinfected drug users.
The relationship between HIV-related immunodeficiency and
liver fibrosis progression has been described in coinfected patients
[6,29,30]; in fact, treating HIV/AIDS with HAART has been
shown to reverse the effect of HIV-related immunodeficiency in
patients with chronic hepatitis C [7,26,29,31].
In this study, decreased serum albumin and increased total
bilirubin were associated with elevated FIB-4 scores. This finding
may facilitate identifying a subpopulation of patients at increased
risk for cirrhosis. It is well known that albumin and bilirubin are
key components of the Child-Turcotte-Pugh score that clinicians
use to assess decompensated liver cirrhosis.
In individuals with history of injection drug use, the duration of
injection use is a surrogate for the duration of HCV infection [32].
As expected, the duration of drug addiction in this study was
related to increased FIB-4 scores.
It has been reported that HCV infection itself lowers both low-
density lipoprotein (LDL) and total cholesterol and that patients
treated for chronic hepatitis C had larger increases in LDL and
total cholesterol from baseline [33]. Interestingly, the current study
did not find a significant association between cholesterol levels and
FIB-4 scores among the HCV/HIV-coinfected patients.
This study has a number of limitations that should be
mentioned. First, the alcohol intake assessment was limited to
one categorical variable (.50 g/day, #50 g/day in the 6-month
period before admission), and there was no information on the
history and complications of alcohol consumption. In previous
studies, however, recent alcohol consumption has been treated as
a dichotomous variable using a threshold of 40–50 grams of
ethanol per day or using the definition of heavy alcohol intake
provided by the US National Institute on Alcohol Abuse and
Alcoholism (NIAAA) [6,9,10]. Second, we used a single measure-
ment of laboratory parameters to calculate the FIB-4 scores which
precluded examining the evolution of fibrosis over time. Further-
more, nearly half of the patients had normal aminotransferases
values, as has been previously described for IDUs [34]; despite the
lack of correlation between liver enzyme alterations and liver
damage, it is possible that FIB-4 scores are affected by normal liver
enzymes [20]. Third, the HAART status of the HIV-positive
patients was represented by a qualitative covariate, which
hindered an analysis of the effect of antiretroviral treatment on
FIB-4.
In summary, this study shows that unhealthy alcohol use
strongly influence FIB-4 in HCV- monoinfected patients, whereas
in the context of HCV/HIV coinfection, HIV-related immune
depression exerts a major negative role on FIB-4 results, with no
significant worsening by alcohol intake.
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